Real-world clinical outcomes of intermediate-risk PAM50 (i-ROR) in HR+/HER2- early breast cancer and eligibility for adjuvant CDK4/6 inhibitors.
Breast cancer research and treatment · Terán S, Illia M, Quevedo MC, Moreno ML, Bianchi MA, Lema L et al.
DOI: 10.1007/s10549-026-08027-y